Aeorema Communications (AEO) shares jumped 24.72% to 55.5p as outlook remains strong
The London-based live events agency said its outlook for 1H22 remains ‘very strong’ and that as a result, revenues are now expected to be greater than any other period on record for the company, being no less than £4.5 million, with a profitable 1H ‘for the first time in many years.’
With revenues typically weighted towards the second half of the financial year, the Company said it remains confident of continued growth in revenues for the full year to 30 June 2022.
Commenting, CEO, Steve Quah of Aeorema Communications said: "This is an incredibly exciting time for us as a business developing a global footprint and we are thrilled to be reporting an expected return to profitability for the first half of the financial year, following a period of successful transition to innovative, hybrid solutions tailored to client requirements.”
Bidstack (BIDS) shares jumped 17.19% to 3.75p following a string of new gaming deals
On Monday, Bidstack announced a series of new gaming partnerships that it said will extend its addressable audience and diversify the brands they can reach in-game with the company.
Under the new partnerships, Bidstack will deliver non-intrusive in-game ads for Gold Town Games (World Hockey Manager), Spinoff Games (Disc Golf Valley) and, in addition, one of Europe's top mobile game developers for an award-winning life simulation title, it reported.
Vela Technologies (VELA) shares rose 15.79% to 0.055p as Phase II trial concludes
Today, the Group said it has been informed by St George Street Capital ("SGSC") that the Clinical Study Report ("CSR") from its ARCADIA Phase II clinical trial has been completed.
The trial assessed a therapy that could treat diabetic patients suffering from COVID-19. Vela holds economic interest in the potential commercialisation of the asset called AZD1656 which was used during the trial which showed a strong trend towards reduced mortality in patients.
Following the trial, SGSC are undertaking commercial discussions with potential licensees and partners to exame options for the next stage of the development and approval process.
Oxford Biomedica (OXB) shares fell 7.07% to 1,079p despite securing new agreements
Shares in the gene and cell therapy group were down despite confirming to investors on Monday that it had signed a new licence and supply agreement (LSA) with Arcellx, as well as an extension of the firm’s existing partnership with Novartis to manufacture lentiviral vectors.
In the past month alone, shares in Oxford Biomedica have shed nearly 25% in value.